helixgyn: breast-ovarian cancer
HELIXGYN is a breast-ovarian cancer monitoring program that analyzes the genetic component that determines its development.
What is HELIXGYN?
Breast ovarian cancer is the consequence of the accumulation of damage (somatic mutations) that forms in the DNA and that the body is unable to repair.
HELIXGYN is a breast-ovarian cancer monitoring program that analyzes the genetic component that determines its development. This test is able to discover if there is an accumulation of DNA damages that are not being repaired, in healthy people that don’t show any symptoms. This has been shown to be an early indicator of the initial phase of tumor development.
Why do the test?
HELIXGYN verifies whether lifestyle and hormonal therapies (used to cope with menopause or for IVF or through contraceptives) have determined a progressive accumulation of damage (somatic mutations) in the DNA and therefore the promotion of the development of the breast ovarian cancer.
In this way, it is possible to directly treat physiological conditions that promote tumor development before it is formed.
To carry out the test, a simple blood sample is sufficient. The sample is sent to the Bioscience Institute laboratories, located at the University of Rome, which performs the extraction and sequencing of circulating free DNA with Next Generation Sequencing (NGS) techniques.
This analysis, repeated over time, allows you to know if damage is accumulating in the DNA which can be harmful for overall health.
DNA Damage Risk Factors
- Genetic predisposition
- Early menstruation
- Late pregnancy
- Early menopause
- Hormone replacement therapy
- Ovarian stimulation
- Unhealthy diet
- HPV virus